Skip to main content

Advertisement

Log in

The Molecular Basis of Carcinogenesis in Barrett’s Esophagus

  • SSAT State-of-the-Art Conference
  • Published:
Journal of Gastrointestinal Surgery

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166–178.

    Article  CAS  PubMed  Google Scholar 

  2. Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Toledano AY, Shyr Y, Washington K. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001;32:368–378.

    Article  CAS  PubMed  Google Scholar 

  3. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669–1676.

    CAS  PubMed  Google Scholar 

  4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.

    Article  CAS  PubMed  Google Scholar 

  5. Souza RF, Morales CP, Spechler SJ. Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus. Aliment Pharmacol Ther 2001;15:1087–1100.

    Article  CAS  PubMed  Google Scholar 

  6. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169–1178.

    Article  CAS  PubMed  Google Scholar 

  7. Younes M, Schwartz MR, Ertan A, Finnie D, Younes A. Fas ligand expression in esophageal carcinomas and their lymph node metastases. Cancer 2000;88:524–528.

    Article  CAS  PubMed  Google Scholar 

  8. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787–791.

    Article  CAS  PubMed  Google Scholar 

  9. Morales CP, Lee EL, Shay JW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer 1998;83:652–659.

    Article  CAS  PubMed  Google Scholar 

  10. Couvelard A, Paraf F, Gratio V, Scoazec JY, Henin D, Degott C, Flejou JF. Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol 2000;192:14–18.

    Article  CAS  PubMed  Google Scholar 

  11. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A 1998;95:548–553.

    Article  CAS  PubMed  Google Scholar 

  12. Aberle H, Schwartz H, Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 1996;61:514–523.

    Article  CAS  PubMed  Google Scholar 

  13. Seery JP, Syrigos KN, Karayiannakis AJ, Valizadeh A, Pignatelli M. Abnormal expression of the E-cadherin-catenin complex in dysplastic Barrett's oesophagus. Acta Oncol 1999;38:945–948.

    Article  CAS  PubMed  Google Scholar 

  14. Souza RF, Spechler SJ. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin 2005;55:334–351.

    Article  PubMed  Google Scholar 

  15. Sullivan PM, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054–1061.

    Article  Google Scholar 

  16. Reid BJ, Blount PL, Rabinovitch PS. Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003;13:369–397.

    Article  PubMed  Google Scholar 

  17. Wongsurawat VJ, Finley JC, Galipeau PC, Sanchez CA, Maley CC, Li X, Blount PL, Odze RD, Rabinovitch PS, Reid BJ. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation. Cancer Epidemiol Biomarkers Prev 2006;15:509–516.

    Article  CAS  PubMed  Google Scholar 

  18. Rygiel AM, Milano F, Ten Kate FJ, de Groot JG, Peppelenbosch MP, Bergman JJ, Krishnadath KK. Assessment of chromosomal gains as compared to DNA content changes is more useful to detect dysplasia in Barrett's esophagus brush cytology specimens. Genes Chromosomes Cancer 2008;47:396–404.

    Article  CAS  PubMed  Google Scholar 

  19. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 2001;96:3071–3083.

    Article  CAS  PubMed  Google Scholar 

  20. Chao DL, Sanchez CA, Galipeau PC, Blount PL, Paulson TG, Cowan DS, Ayub K, Odze RD, Rabinovitch PS, Reid BJ. Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. Clin Cancer Res 2008;14:6988–6995.

    Article  CAS  PubMed  Google Scholar 

  21. Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, Blount PL, Rabinovitch PS. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839–2848.

    Article  CAS  PubMed  Google Scholar 

  22. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, Ayub K, Rabinovitch PS, Vaughan TL, Reid BJ. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 2007;4:e67.

    Article  PubMed  Google Scholar 

  23. Rygiel AM, van Baal JW, Milano F, Wang KK, Ten Kate FJ, Fockens P, Rosmolen WD, Bergman JJ, Peppelenbosch MP, Krishnadath KK. Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population. Cancer 2007;109:1980–1988.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rhonda F. Souza.

Additional information

“This paper was originally presented as part of the SSAT/AGA/ASGE State-of-the-Art Conference, Barrett’s Esophagus, Dysplasia, and Early Esophageal Adenocarcinoma: Managing the Transition, at the SSAT 50th Annual Meeting, June 2009, in Chicago, Illinois. The other articles presented in the conference were Sarosi GA, Introduction: Barrett’s Esophagus, Dysplasia, and Early Esophageal Adenocarcinoma: Managing the Transition; DeMeester SR, Reflux, Barrett’s and Adenocarcinoma of the Esophagus: Can We Disrupt the Pathway?; Wang KK, Endoscopic Treatment for Barrett's Esophagus and Early Esophageal Cancer; and Pennathur A and Luketich JD, Minimally Invasive Esophagectomy for Barrett's with High Grade Dysplasia and Early Adenocarcinoma of the Esophagus.”

This work was supported by the Office of Medical Research, Department of Veterans Affairs, Dallas, TX (R.F.S.) and the National Institutes of Health (R01-DK63621 to R.F.S).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Souza, R.F. The Molecular Basis of Carcinogenesis in Barrett’s Esophagus. J Gastrointest Surg 14, 937–940 (2010). https://doi.org/10.1007/s11605-009-1145-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-009-1145-7

Keywords

Navigation